Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Novigenix SA logo — Leader in Immuno-Transcriptomic Precision Medicine solutions

Novigenix SA

Leader in Immuno-Transcriptomic Precision Medicine solutions

Founded 2014 Switzerland Lausanne, Switzerland 26 employees Series B Total: $21.00M AI, Analytics +4

General Information

Company Name Novigenix SA
Founded Year 2014
Location Switzerland Lausanne, Switzerland
Founders / Decision Makers
Team member Team member
Employees 26
Industries AI, Analytics, Biotechnology +3
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Novigenix SA. To contact Novigenix SA, visit novigenix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Novigenix SA compare?

A PDF of Novigenix SA and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Novigenix SA soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Novigenix SA

NOVIGENIX is a Swiss precision medicine company founded in 2014 that focuses on leveraging ImmunoTranscriptomic technologies to revolutionize disease management, with a primary focus on cancer. Through their proprietary LITOseek platform, which incorporates advanced Machine Learning and artificial intelligence techniques, the company aims to use patient multi-omics data to map the immune system's response to disease onset and progression, ultimately providing personalized insights and solutions to optimize patient therapeutic journeys. This innovation is expected to lead to improved patient outcomes by identifying illnesses, optimizing therapies, and monitoring disease recurrence. Their product roadmap includes immuno-oncology patient stratification tools, early detection and recurrence monitoring for colorectal cancer, and therapy optimization systems for managing cancer patients. In their latest funding round, NOVIGENIX secured a notable $20.00M Series B investment on 15 November 2022. This investment is a testament to the confidence that investors have in the potential of the company's technologies and their ability to make a significant impact in the biotechnology industry. With its headquarters in Switzerland, NOVIGENIX is strategically positioned at the heart of a renowned hub for biotechnology innovation. Their cutting-edge approach and recent investment injection position them well for driving advancements in disease management and patient outcomes.

Business keywords: Precision Medicine, ImmunoTranscriptomics, AI in Healthcare, Cancer Management, Multi-omics Data Analysis, Therapy Optimization, Immuno-oncology, Disease Recurrence Monitoring, Colorectal Cancer, Patient Stratification, Personalized Medicine, Switzerland, LITOseek Platform

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $20.00M -
15 Nov 2022
Grant €1.00M 1
Eurostars
21 Jan 2020

Novigenix SA Alternatives & Competitors

View All Alternatives
Novigenix SA vs
Pear Bio
Pear Bio United Kingdom

Patient-centered cancer precision medicine

Series A
8 employees
Biotechnology, Health Care
Compare Novigenix SA vs Pear Bio
Novigenix SA vs
ACT Genomics
ACT Genomics Taiwan

Make Personalized Medicine Accessible To All.

Venture round
121 employees
Biotechnology, Health Care
Compare Novigenix SA vs ACT Genomics
Novigenix SA vs
LinusBio
LinusBio United States

Precision Exposome Medicine

35 employees
Biotechnology, Health Care
View all alternatives

FAQ About Novigenix SA

Leader in Immuno-Transcriptomic Precision Medicine solutions
Novigenix SA was founded in 2014.
Novigenix SA is headquartered in Lausanne, Switzerland.
Novigenix SA operates in AI, Analytics, Biotechnology, Health Care, Life Sciences and Machine Learning. Its work centres on Precision Medicine, ImmunoTranscriptomics, AI in Healthcare and Cancer Management.
Novigenix SA has approximately 26 employees.
Novigenix SA has completed 2 funding rounds, raising a total of $21.00M. The latest funding stage is Series B.
Top alternatives and competitors to Novigenix SA include Pear Bio, ACT Genomics, LinusBio, Lantern Pharma Inc. (Nasdaq: LTRN), Predicine. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Novigenix SA and Pear Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Novigenix SA, https://bouncewatch.com/company/novigenix, updated 29 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes